Kaisa Health Group Holdings Limited (HK:0876)
:0876
Want to see HK:0876 full AI Analyst Report?
0876 Stock Chart & Stats
HK$0.09
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.09
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.02 - HK$0.22
Previous CloseN/A
Volume60.00K
Average Volume (3M)76.64M
Market Cap
HK$368.08M
Enterprise Value-HK$87.87M
Total Cash (Recent Filing)HK$109.60M
Total Debt (Recent Filing)HK$13.46M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding5,042,139,000
10 Day Avg. Volume53,429,215
30 Day Avg. Volume76,644,739
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.88
Price to Sales (P/S)2.54
P/FCF Ratio-6.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative LeverageLow reported debt relative to equity reduces near-term solvency and refinancing risk, giving management optionality to fund operations or restructuring without immediate liquidity pressure. This structural balance-sheet flexibility matters when cash flow is negative and external financing may be needed.
Healthcare Industry ExposureExposure to the medical instruments & supplies sector provides durable demand drivers tied to healthcare spending and aging populations. Structural industry demand and recurring procurement cycles can support a recovery in revenues if the company stabilizes operations and re-engages customers.
Underlying Gross Margin FoundationA still-reasonable gross margin implies product-level profitability exists despite recent compression. That structural cost-to-revenue relationship means cost control or revenue restoration could more directly restore operating profitability, assuming fixed costs and non-operating pressures are addressed.
Bears Say
Sustained Revenue DeclineMulti-year revenue contraction, capped by a sharp 2025 decline, erodes scale economics and market position. Durable revenue weakness limits margin recovery, reduces bargaining power with suppliers, and complicates plans to return to sustainable profitability without significant strategic change.
Persistent Negative Cash FlowConsistent operating and free cash flow deficits force reliance on external funding or equity issuance, reducing financial flexibility. Over time, sustained cash burn constrains investment in product development, sales, and working capital, raising structural risk if profitability is not restored.
Volatile Losses And Capital ErosionRepeated losses and shrinking equity/assets indicate capital erosion and negative ROE, undermining creditworthiness and investor confidence. Structurally, this reduces the firm’s ability to fund growth internally and increases the likelihood of dilutive or restrictive financing events if trends continue.
Kaisa Health Group Holdings Limited News
0876 FAQ
What was Kaisa Health Group Holdings Limited’s price range in the past 12 months?
Kaisa Health Group Holdings Limited lowest stock price was HK$0.02 and its highest was HK$0.22 in the past 12 months.
What is Kaisa Health Group Holdings Limited’s market cap?
Kaisa Health Group Holdings Limited’s market cap is HK$368.08M.
When is Kaisa Health Group Holdings Limited’s upcoming earnings report date?
Kaisa Health Group Holdings Limited’s upcoming earnings report date is Sep 02, 2026 which is in 85 days.
How were Kaisa Health Group Holdings Limited’s earnings last quarter?
Kaisa Health Group Holdings Limited released its earnings results on Mar 25, 2026. The company reported -HK$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.007.
Is Kaisa Health Group Holdings Limited overvalued?
According to Wall Street analysts Kaisa Health Group Holdings Limited’s price is currently Overvalued.
Does Kaisa Health Group Holdings Limited pay dividends?
Kaisa Health Group Holdings Limited pays a Notavailable dividend of HK$0.037 which represents an annual dividend yield of N/A. See more information on Kaisa Health Group Holdings Limited dividends here
What is Kaisa Health Group Holdings Limited’s EPS estimate?
Kaisa Health Group Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kaisa Health Group Holdings Limited have?
Kaisa Health Group Holdings Limited has 5,042,139,000 shares outstanding.
What happened to Kaisa Health Group Holdings Limited’s price movement after its last earnings report?
Kaisa Health Group Holdings Limited reported an EPS of -HK$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Kaisa Health Group Holdings Limited?
Currently, no hedge funds are holding shares in HK:0876
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kaisa Health Group Holdings Limited
Kaisa Health Group Holdings Limited operates as an investment holding company, primarily focused on the manufacturing and global distribution of dental prosthetics across the People's Republic of China and international markets. Its comprehensive product line includes items such as crowns, bridges, full and partial removable dentures, dental implants, and full-cast restorations. The company also delivers public health and general medical services. Moreover, the group's activities extend to holding investments in convertible bonds, providing medical technology solutions, engaging in healthcare project development, offering medical consultation, and other diverse medical services. Established in 1971, the entity was known as Mega Medical Technology Limited until its rebranding in January 2018, and its headquarters are located in Central, Hong Kong.
Technical Analysis
Shandong Weigao Group Medical Polymer Co
―
―
PW Medtech Group Ltd.
―
Shanghai Kindly Medical Instruments Co., Ltd. Class H
―
Shanghai Conant Optical Co. Ltd. Class H
―